12 citations,
August 2020 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
The conversation discusses the tension theory as a cause of male pattern baldness (MPB), suggesting that scalp tension and reduced subcutaneous fat layer contribute to hair loss. Treatments mentioned include Minoxidil, finasteride, microneedling, scalp massages, and Botox.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
The conversation discusses complementary treatments for hair loss while using finasteride and minoxidil, including scalp massagers, scrubs, coconut oil, and vitamin supplements. The user seeks opinions on these additional treatments.